|
|
|
|
Unitat de Farmacologia, Department de Farmacologia i Química Terapèutica, Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain
Cardiac expression of genes involved in fatty acid metabolism may suffer
alterations depending on the substrate availability. We studied how
troglitazone, an antidiabetic drug that selectively activates peroxisome
proliferator-activated receptor
(PPAR
), affected the expression
of several of these genes. A single-day troglitazone administration (100
mg/kg/day) did not significantly alter plasma free fatty acids or triglyceride
levels. In contrast, a 10-day period of troglitazone treatment significantly
reduced plasma free fatty acids and triglyceride levels by 74% (P
< 0.001) and 56% (P < 0.01), respectively. Cardiac mRNA
expression of acyl-CoA oxidase (ACO) increased (8.3-fold induction) after
1-day troglitazone treatment, whereas after 10 days of treatment ACO mRNA
levels were dramatically reduced (98% reduction, P < 0.02), as
well as those of uncoupling protein 3 (41% reduction, P = 0.05). The
mRNA expression of PPAR
and several PPAR target genes, such as medium
chain acyl-CoA dehydrogenase or fatty acid translocase were not altered after
10 days of troglitazone treatment, whereas muscle-type carnitine
palmitoyltransferase I increased 1.7-fold (P < 0.05). The
reduction in ACO expression in the hearts of 10-day troglitazone-treated mice
was accompanied by an increase in the protein levels of the transcriptional
repressor chicken ovalbumin upstream promoter transcription factor II (COUP-TF
II). Electrophoretic mobility shift assays performed with COUP-TF II antibody
to examine its interaction with a labeled peroxisome proliferator response
element probe showed enhanced binding of COUP-TFII in cardiac nuclear extracts
from troglitazone-treated mice for 10 days but not in the control nuclear
extracts. Overall, the findings presented here show that 10 days of
troglitazone treatment decreased expression of the ACO gene through a
mechanism involving the transcriptional repressor COUP-TF II.
Received December 24, 2002; accepted June 13, 2003.
Address correspondence to: Dr. Manuel Vázquez-Carrera, Unitat de Farmacologia, Facultat de Farmàcia, Diagonal 643, E-08028 Barcelona, Spain. E-mail: mvaz{at}farmacia.far.ub.es
This article has been cited by other articles:
![]() |
K. I. Shoghi, B. N. Finck, K. B. Schechtman, T. Sharp, P. Herrero, R. J. Gropler, and M. J. Welch In Vivo Metabolic Phenotyping of Myocardial Substrate Metabolism in Rodents: Differential Efficacy of Metformin and Rosiglitazone Monotherapy Circ Cardiovasc Imaging, September 1, 2009; 2(5): 373 - 381. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. N. Finck The PPAR regulatory system in cardiac physiology and disease Cardiovasc Res, January 15, 2007; 73(2): 269 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Spann, S. Kang, A. C. Li, A. Z. Chen, E. P. Newberry, N. O. Davidson, S. T. Y. Hui, and R. A. Davis Coordinate Transcriptional Repression of Liver Fatty Acid-binding Protein and Microsomal Triglyceride Transfer Protein Blocks Hepatic Very Low Density Lipoprotein Secretion without Hepatosteatosis J. Biol. Chem., November 3, 2006; 281(44): 33066 - 33077. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Rodriguez-Calvo, M. Jove, T. Coll, A. Camins, R. M. Sanchez, M. Alegret, M. Merlos, M. Pallas, J. C. Laguna, and M. Vazquez-Carrera PGC-1{beta} Down-Regulation Is Associated With Reduced ERR{alpha} Activity and MCAD Expression in Skeletal Muscle of Senescence-Accelerated Mice. J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2006; 61(8): 773 - 780. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Allen, K. B. Piontek, E. Garrett-Mayer, M. Garcia-Gonzalez, K. L. Gorelick, and G. G. Germino Loss of polycystin-1 or polycystin-2 results in dysregulated apolipoprotein expression in murine tissues via alterations in nuclear hormone receptors Hum. Mol. Genet., January 1, 2006; 15(1): 11 - 21. [Abstract] [Full Text] [PDF] |
||||